Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K9 | P80192 | 9/20 | 0.61 |
| ▸ | MAP3K11 | Q16584 | 9/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.61 |
| ▸ | PRKCG | P05129 | 5/20 | 0.61 |
| ▸ | PRKCB | P05771 | 5/20 | 0.61 |
| ▸ | PRKCA | P17252 | 5/20 | 0.61 |
| ▸ | PRKCH | P24723 | 5/20 | 0.61 |
| ▸ | PRKCI | P41743 | 5/20 | 0.61 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.61 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.61 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.61 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.61 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.61 |
| ▸ | MAP3K10 | Q02779 | 4/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5173554 | 0.91 | MAP3K9 (0.61) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL12219429 | 0.78 | MAP3K9 (0.66) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL3075228 | 0.78 | MAP3K9 (0.80) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL17228824 | 0.77 | MAP3K9 (0.64) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL3072275 | 0.76 | MAP3K11 (1.00) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL3082217 | 0.74 | MAP3K9 (1.00) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL23369901 | 0.72 | MAP3K9 (0.61) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL17451746 | 0.72 | MAP3K9 (0.61) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL20382171 | 0.71 | MAP3K9 (0.57) | MAP3K9MAP3K11PRKD3PRKCGPRKCB | |
| SCHEMBL7354146 | 0.71 | MAP3K9 (0.68) | MAP3K9MAP3K11PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| EP-2364699-A1 | Joint use of sulfonamide based compound with angiogenesis inhibitor | Eisai R&D Management Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1088823-B1 | Fused pyrrolocarbazoles | CEPHALON INC (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-0785938-B1 | FUSED PYRROLOCARBAZOLES | CEPHALON INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1088823-A1 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0785938-A1 | FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5594009-A | KINASE INHIBITORS, TROPHIC FACTOR-INDUCED ACTIVITY ENHANCEMENT, CELL SURVIVAL | CEPHALON, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5475110-A | Treating nervous system disorders and inflammation, inhibiting protein and tyrosine kinases, inhibiting cell growth | CEPHALON, INC. (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | MAP3K9 1906/4885MAP3K11 1608/4885PRKD3 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.